Cited by 200Neuropeptides and Animal PhysiologyNeuroendocrine regulation and behaviorChemical Synthesis and Analysis

The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Griebel, Guy, Holsboer, Florian·2012·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

The search for novel drugs for treating psychiatric disorders is driven by the growing medical need to improve on the effectiveness and side-effect profile of currently available therapies. Given the wealth of preclinical data supporting the role of neuropeptides in modulating behaviour, pharmaceutical companies have been attempting to target neuropeptide receptors for over two decades. However, clinical studies with synthetic neuropeptide ligands have been unable to confirm the promise predicted by studies in animal models. Here, we analyse preclinical and clinical results for neuropeptide receptor ligands that have been studied in clinical trials for psychiatric diseases, including agents that target the receptors for tachykinins, corticotropin-releasing factor, vasopressin and neurotensin, and suggest new ways to exploit the full potential of these candidate drugs.

Integrity signals

Registry

Crossref · 10.1038/nrd3702

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Self-citation
Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Characterization of a 41-Residue Ovine Hypothalamic Peptide that Stimulates Secretion of Corticotropin and β-Endorphin
Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Stress and Depression
Hammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Self-citation
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Peptidergic neurones
Hökfelt, T. G. M., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,552

Show all 176 references

Research works printed but not linked: 6

Chappell, P. Effect of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. In: Proceedings of the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2002).
Ratti, E. et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727–733 (2011). · DOI
Liebowitz, M., Sheehan, D., Melia, L. A. & Siffert, J. Safety and efficacy of AV608 in subjects with social anxiety disorder. In: Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2007).
Wernet, W. et al. In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Program No. 560.16. 2008 Neuroscience Meeting Planner (Washington DC; Society for Neuroscience; 2008).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). (American Psychiatric Association, Washington DC, 2000).
Kirsch, I. The Emperor's New Drugs: Exploring the Antidepressant Myth (Bodley Head, 2010).

Sorted by citations

Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Structure of the agonist-bound neurotensin receptor
White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 527
Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement
Koob, G. F. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.023 · Cited by 477
HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Detecting Activated Cell Populations Using Single-Cell RNA-Seq
Wu, Y. E., Pan, L., Zuo, Y., Li, X., & Hong, W. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.026 · Cited by 438
50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 430
Self-citation
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq–based resource for pain and sensory neuroscience research
Ray, P. R., Torck, A., Quigley, L. D., Wangzhou, A., Neiman, M., Rao, C., Lam, T., Kim, J., Kim, T. H., Zhang, M. Q., et al. (2018) · Pain · doi:10.1097/j.pain.0000000000001217 · Cited by 346
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López‐Giménez, J. F., & González‐Maeso, J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_478 · Cited by 325
The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress
Zelikowsky, M., Hui, M., Karigo, T., Choe, A., Yang, B., Blanco, M. R., Beadle, K., Gradinaru, V., Deverman, B. E., & Anderson, D. J. (2018) · Cell · doi:10.1016/j.cell.2018.03.037 · Cited by 290
The Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Deussing, J. M., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 271
Region-specific roles of the corticotropin-releasing factor–urocortin system in stress
Henckens, M. J. A. G., Deussing, J. M., & Chen, A. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.94 · Cited by 248
The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions
Dunlop, B. W., & Wong, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.010 · Cited by 271
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli
Egloff, P., Hillenbrand, M., Klenk, C., Batyuk, A., Heine, P., Balada, S. B., Schlinkmann, K. M., Scott, D. J., Schütz, M., & Plückthun, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317903111 · Cited by 216
Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice
Peters, S., Slattery, D. A., Uschold‐Schmidt, N., Reber, S. O., & Neumann, I. D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.01.021 · Cited by 189
Emerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 174
Are We Getting Closer to Valid Translational Models for Major Depression?
Berton, O., Hahn, C.-G., & Thase, M. E. (2012) · Science · doi:10.1126/science.1222940 · Cited by 160
β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors
Slosky, L. M., Bai, Y., Tóth, K., Ray, C., Rochelle, L. K., Badea, A., Chandrasekhar, R., Pogorelov, V. M., Abraham, D., Atluri, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.053 · Cited by 151
The neurobiological correlates of childhood adversity and implications for treatment
Tyrka, A. R., Burgers, D. E., Philip, N. S., Price, L. H., & Carpenter, L. L. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12143 · Cited by 142
“There are no other such drugs in advanced clinical development (90).”
Background
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Cryo-EM structure of an activated GPCR–G protein complex in lipid nanodiscs
Zhang, M., Gui, M., Wang, Z., Gorgulla, C., Yu, J. J., Wu, H., Sun, Z.-Y. J., Klenk, C., Merklinger, L., Morstein, L., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-00554-6 · Cited by 125
Biophysical characterization of membrane proteins in nanodiscs
Inagaki, S., Ghirlando, R., & Grisshammer, R. (2012) · Methods · doi:10.1016/j.ymeth.2012.11.006 · Cited by 120
Brain galanin system genes interact with life stresses in depression-related phenotypes
Juhász, G., Hullám, G., Eszlári, N., Gonda, X., Antal, P., Anderson, I. M., Hökfelt, T. G. M., Deakin, J. F. W., & Bagdy, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403649111 · Cited by 107
Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects?
Belzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106
Structural prerequisites for G-protein activation by the neurotensin receptor
Krumm, B. E., White, J. F., Shah, P., & Grisshammer, R. (2015) · Nature Communications · doi:10.1038/ncomms8895 · Cited by 103
Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice
Zhang, R., Asai, M., Mahoney, C. E., Joachim, M., Shen, Y., Gunner, G., & Majzoub, J. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.136 · Cited by 103
Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder
Dunlop, B. W., Binder, E. B., Iosifescu, D., Mathew, S. J., Neylan, T. C., Pape, J. C., Carrillo-Roa, T., Green, C., Kinkead, B., Grigoriadis, D., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.024 · Cited by 96
Evidence for the role of corticotropin-releasing factor in major depressive disorder
Waters, R. P., Rivalan, M., Bangasser, D. A., Deussing, J. M., Ising, M., Wood, S. K., Holsboer, F., & Summers, C. H. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.011 · Cited by 93
Self-citation
Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention
Xie, J. Y., Felice, M. D., Kopruszinski, C. M., Eyde, N., LaVigne, J. E., Remeniuk, B., Hernandez, P., Yue, X., Goshima, N., Ossipov, M. H., et al. (2017) · Cephalalgia · doi:10.1177/0333102417702120 · Cited by 87
Endocrinology and the brain: corticotropin-releasing hormone signaling
Inda, C., Armando, N. G., Claro, P. A. D. S., & Silberstein, S. (2017) · Endocrine Connections · doi:10.1530/ec-17-0111 · Cited by 81
Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala
Kim, T.-K., Kim, J., Park, J. Y., Lee, J. E., Choi, J., Kim, H., Lee, E. H., Kim, S.-W., Lee, J.-K., Kang, H., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.004 · Cited by 76
Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease
Lundh, S. H., Nilsson, N., Soylu-Kucharz, R., Kirik, D., & Petersén, Å. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt203 · Cited by 78
Hippocampal neurogenesis: a biomarker for depression or antidepressant effects? Methodological considerations and perspectives for future research
Tanti, A., & Belzung, C. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1612-z · Cited by 75
Structure and dynamics of a constitutively active neurotensin receptor
Krumm, B. E., Lee, S., Bhattacharya, S., Botos, I., White, C. F., Du, H., Vaidehi, N., & Grisshammer, R. (2016) · Scientific Reports · doi:10.1038/srep38564 · Cited by 72
Ethological concepts enhance the translational value of animal models
Peters, S. M., Pothuizen, H. H. J., & Spruijt, B. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.043 · Cited by 70
Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?
Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 73
Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences
Grillon, C., Robinson, O. J., Cornwell, B., & Ernst, M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0445-1 · Cited by 73
Neuroscience-driven discovery and development of sleep therapeutics
Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63
Self-citation
The Biology of Vasopressin
Sparapani, S., Millet-Boureima, C., Oliver, J., Mu, K., Hadavi, P., Kalostian, T., Ali, N., Avelar, C. M., Bardies, M., Barrow, B., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010089 · Cited by 64
Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs
Ong, J. J. Y., Wei, D. Y., & Goadsby, P. J. (2018) · Drugs · doi:10.1007/s40265-018-0865-y · Cited by 61
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide
Barde, S. S., Rüegg, J., Prud’homme, J., Ekström, T. J., Palkovits, M., Turecki, G., Bagdy, G., Ihnatko, R., Theodorsson, E., Juhász, G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617824113 · Cited by 61
Anxiogenic and Stressor Effects of the Hypothalamic Neuropeptide RFRP-3 Are Overcome by the NPFFR Antagonist GJ14
Kim, J. S., Brownjohn, P. W., Dyer, B. S., Beltramo, M., Walker, C. S., Hay, D. L., Painter, G. F., Tyndall, J. D. A., & Anderson, G. M. (2015) · Endocrinology · doi:10.1210/en.2015-1532 · Cited by 57
Leading compounds for the validation of animal models of psychopathology
Micale, V., Kučerová, J., & Šulcová, A. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1692-9 · Cited by 58
Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 60
Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.
Buckley, M. M., O’Mahony, S. M., & O’Malley, D. (2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8846 · Cited by 55
Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators
Pinkerton, A. B., Peddibhotla, S., Yamamoto, F., Slosky, L. M., Bai, Y., Maloney, P., Hershberger, P., Hedrick, M. P., Falter, B., Ardecky, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00340 · Cited by 54
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 54
Role of Corticotropin Releasing Factor in the Neuroimmune Mechanisms of Depression: Examination of Current Pharmaceutical and Herbal Therapies
Jiang, Y., Peng, T., Gaur, U., Silva, M., Little, P. J., Chen, Z., Qiu, W., Zhang, Y., & Zheng, W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00290 · Cited by 55
Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray
Wang, P., Li, H., Barde, S. S., Zhang, M., Sun, J., Wang, T., Zhang, P., Luo, H., Wang, Y., Yang, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609198113 · Cited by 53
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: An fMRI study
Lee, R. J., Coccaro, E. F., Cremers, H., McCarron, R., Lu, S.-F., Brownstein, M. J., & Simon, N. G. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00100 · Cited by 50
Biological substrates underpinning diagnosis of major depression
Sibille, E. L., & French, B. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000436 · Cited by 53
The Role of Neuropeptides in Suicidal Behavior: A Systematic Review
Serafini, G., Pompili, M., Lindqvist, D., Dwivedi, Y. K., & Girardi, P. (2013) · BioMed Research International · doi:10.1155/2013/687575 · Cited by 49
Discovery of ML314, a Brain Penetrant Nonpeptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor
Peddibhotla, S., Hedrick, M. P., Hershberger, P., Maloney, P., Li, Y., Milewski, M., Gosalia, P., Gray, W., Mehta, A., Sugarman, E. D., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400176n · Cited by 47
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Grillon, C., Hale, E., Lieberman, L., Davis, A., Pine, D. S., & Ernst, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.316 · Cited by 47
Neuropeptides and oligopeptidases in schizophrenia
Rodríguez, B., Nani, J. V. S., Almeida, P. G. C., Brietzke, E. M., Lee, R. S., & Hayashi, M. A. F. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.024 · Cited by 47
DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder
Pape, J. C., Carrillo‐Roa, T., ROTHBAUM, B. O., Nemeroff, C. B., Czamara, D., Zannas, A. S., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Mayberg, H. S., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0569-x · Cited by 45
Crystal structure of the human NK 1 tachykinin receptor
Yin, J., Chapman, K., Clark, L. D., Shao, Z., Borek, D., Xu, Q., Wang, J., & Rosenbaum, D. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812717115 · Cited by 45
ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse
Barak, L. S., Bai, Y., Peterson, S. M., Evron, T., Urs, N. M., Peddibhotla, S., Hedrick, M. P., Hershberger, P., Maloney, P., Chung, T. D. Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00291 · Cited by 44
Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543
Dournes, C., Beeské, S., Belzung, C., & Griebel, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.019 · Cited by 47
Self-citation
Neurokinin receptor antagonism: a patent review (2014-present)
Muñoz, M., & Coveñas, R. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1769599 · Cited by 41
Bright Fluorescence Monitoring System Utilizing Zoanthus sp. Green Fluorescent Protein (ZsGreen) for Human G-Protein-Coupled Receptor Signaling in Microbial Yeast Cells
Nakamura, Y., Ishii, J., & Kondo, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082237 · Cited by 40
Neuropeptide Systems and Schizophrenia
LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39
Distinct populations of corticotropin-releasing factor (CRF) neurons mediate divergent yet complementary defensive behaviors in response to a threat
Chudoba, R., & Dabrowska, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109461 · Cited by 38
Therapeutic approaches targeting the neurotensin receptors
Iyer, M. R., & Kunos, G. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1866539 · Cited by 37
Vasopressin V1B receptor antagonists as potential antidepressants
Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34
Structural Dynamics and Thermostabilization of Neurotensin Receptor 1
Lee, S., Bhattacharya, S., Tate, C. G., Grisshammer, R., & Vaidehi, N. (2015) · The Journal of Physical Chemistry B · doi:10.1021/jp510735f · Cited by 34
Corticotropin-releasing factor peptide antagonists: Design, characterization and potential clinical relevance
Rivier, J., & RIVIER, C. L. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.10.006 · Cited by 33
SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands
Huber, S., Casagrande, F., Hug, M. N., Wang, L., Heine, P., Kummer, L., Plückthun, A., & Hennig, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175842 · Cited by 34
The diverse role of corticotropin-releasing factor (CRF) and its CRF1 and CRF2 receptors under pathophysiological conditions: Insights into stress/anxiety, depression, and brain injury processes
Domin, H., & Śmiałowska, M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105748 · Cited by 31
Blood-brain barrier transport kinetics of the neuromedin peptides NMU, NMN, NMB and NT
Gevaert, B., Wynendaele, E., Stalmans, S., Bracke, N., D’Hondt, M., Smolders, I. J., Eeckhaut, A. V., & Spiegeleer, B. M. J. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.051 · Cited by 29
Orphan neuropeptides and receptors: Novel therapeutic targets
Fricker, L. D., & Devi, L. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.006 · Cited by 29
Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation
Dim, N., Perepelyuk, M., Gomes, O., Thangavel, C., Liu, Y., Den, R. B., Lakshmikuttyamma, A., & Shoyele, S. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0124-2 · Cited by 27
Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries
Ranganathan, A., Heine, P., Rudling, A., Plückthun, A., Kummer, L., & Carlsson, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00646 · Cited by 28
DrosophilaTachykininergic Neurons Modulate the Activity of Two Groups of Receptor-Expressing Neurons to Regulate Aggressive Tone
Wohl, M. P., Liu, J., & Asahina, K. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1734-22.2023 · Cited by 27
Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons
Barde, S. S., Benitez, J. A., Zhong, W., Solarz, A., Mei, I., Prud’homme, J., Palkovits, M., Turecki, G., Mulder, J., Uhlén, M., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.09.004 · Cited by 28
Neuroendocrine Regulation of Anxiety: Beyond the Hypothalamic‐Pituitary‐Adrenal Axis
Borrow, A. P., Stranahan, A. M., Suchecki, D., & Yunes, R. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12403 · Cited by 27
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A–E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium
Al‐Awadhi, F. H., Gao, B., Rezaei, M. A., Kwan, J. C., Li, C., Ye, T., Paul, V. J., & Luesch, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00885 · Cited by 24
Differential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression
Xu, F., Yang, H. J., Chen, J., Wu, Q., Gong, W., Zhang, J., Shao, W., Mu, J., Yang, D., Yang, Y., et al. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0543-y · Cited by 23
Examining the Role of Vasopressin in the Modulation of Parental and Sexual Behaviors
Zimmermann-Peruzatto, J. M., Lazzari, V. M., de Moura, A. C., Almeida, S., & Giovenardi, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00130 · Cited by 23
Identification of a Role for the Ventral Hippocampus in Neuropeptide S-Elicited Anxiolysis
Dine, J., Ionescu, I. A., Stepan, J., Yen, Y.-C., Holsboer, F., Landgraf, R., Eder, M., & Schmidt, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060219 · Cited by 23
Self-citation
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436
Katz, D. A., Liu, W., Locke, C. S., Dutta, S., & Tracy, K. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4089-5 · Cited by 23
Understanding and Predicting Antidepressant Response: Using Animal Models to Move Toward Precision Psychiatry
Herzog, D. P., Beckmann, H., Lieb, K., Ryu, S., & Müller, M. B. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00512 · Cited by 26
MiRNA mimic screen for improved expression of functional neurotensin receptor from HEK 293 cells
Xiao, S., Chen, Y., Betenbaugh, M. J., Martin, S. E., & Shiloach, J. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25567 · Cited by 22
Stress Impacts the Regulation Neuropeptides in the Rat Hippocampus and Prefrontal Cortex
Li, W., Papilloud, A., Lozano‐Montes, L., Zhao, N., Ye, X., Zhang, X., Sandi, C., & Rainer, G. (2018) · PROTEOMICS · doi:10.1002/pmic.201700408 · Cited by 23
Neurotensin and Dynorphin Bi-Directionally Modulates CeA Inhibition of oval BNST Neurons in Male Mice
Normandeau, C. P., Torruella-Suárez, M. L., Sarret, P., McElligott, Z. A., & Dumont, É. C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.031 · Cited by 22
The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and d-cycloserine
Philbert, J., Belzung, C., & Griebel, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3020-1 · Cited by 24
Self-citation
Human fear acquisition deficits in relation to genetic variants of the corticotropin‐releasing hormone receptor 1 and the serotonin transporter — revisited
Heitland, I., Groenink, L., van Gool, J. M. G., Domschke, K., Reif, A., & Baas, J. M. P. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12276 · Cited by 23
Neuroimmune Cross Talk in the Gut. Neuroendocrine and neuroimmune pathways contribute to the pathophysiology of irritable bowel syndrome
O’Malley, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00272.2016 · Cited by 21
Molecular Plasticity of the Nucleus Accumbens Revisited—Astrocytic Waves Shall Rise
Kardos, J., Dobolyi, Á., Szabó, Z. M., Simon, Á., Lourmet, G. S., Palkovits, M., & Héja, L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1641-z · Cited by 22
Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Rees, C. L., White, C. M., & Ascoli, G. A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170414163506 · Cited by 20
Activation Dynamics of the Neurotensin G Protein-Coupled Receptor 1
Cong, X., Fiorucci, S., & Golebiowski, J. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00216 · Cited by 20
Stress-Related Brain Neuroinflammation Impact in Depression: Role of the Corticotropin-Releasing Hormone System and P2X7 Receptor
Silberstein, S., Liberman, A. C., Claro, P. A. D. S., Ugo, M. B., Deussing, J. M., & ARZT, E. S. (2021) · NeuroImmunoModulation · doi:10.1159/000515130 · Cited by 19
Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder
Hodgins, G. E., Blommel, J. G., Dunlop, B. W., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Mayberg, H. S., & Harvey, P. D. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000858 · Cited by 20
A Polymorphism in the Crhr1 Gene Determines Stress Vulnerability in Male Mice
Labermaier, C., Kohl, C., Hartmann, J., Devigny, C., Altmann, A., Weber, P. C., Arloth, J., Quast, C., Wagner, K. V., Scharf, S. H., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1986 · Cited by 20
Self-citation
Indications of success: Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development
Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 19
Neuroendocrine and Neurochemical Processes in Depression
Cowen, P. J. (2015) · Psychopathology Review · doi:10.5127/pr.034513 · Cited by 19
The Nucleus Accumbens CRH–CRHR1 System Mediates Early-Life Stress-Induced Sleep Disturbance and Dendritic Atrophy in the Adult Mouse
Wang, T., Ma, Y., Zhang, C., Liu, X., Sun, Y., Wang, H., Wang, H., Zhong, Y.-H., Su, Y., Li, J., et al. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00903-z · Cited by 18
A cleavable ligand column for the rapid isolation of large quantities of homogeneous and functional neurotensin receptor 1 variants from E. coli
Egloff, P., Deluigi, M., Heine, P., Balada, S. B., & Plückthun, A. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.10.006 · Cited by 18
Peripheral Biomarkers in Animal Models of Major Depressive Disorder
Carboni, L. (2013) · Disease Markers · doi:10.1155/2013/284543 · Cited by 18

Authors: Griebel, G., & Holsboer, F.
Affiliations: Sanofi (France) (FR)
Max Planck Institute of Psychiatry (DE)
Corresponding author: Griebel, Guy
ORCID: Griebel, Guy
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2012-05-18
Volume: 11
Issue: 6
Pages: 462-478
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd3702
OpenAlex: W2089617519
Cited by: 194
References: 176
Citations by year: 2026: 5 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 20 · 2015: 22 · 2014: 19 · 2013: 23 · 2012: 9
FWCI: 2.50
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: psychiatric drug development, tachykinins, corticotropin-releasing factor, vasopressin, neurotensin, clinical translation, adverse effects
MeSH terms: Animals, Mental Disorders, Corticotropin-Releasing Hormone, Humans, Ligands, Neurotensin, Psychotropic Drugs, Vasopressins, Tachykinins, Drug Delivery Systems, Receptors, Vasopressin, Receptors, Neuropeptide, Receptors, Corticotropin-Releasing Hormone, Receptors, Neurotensin, Receptors, Tachykinin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks